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Abstract  Coronary  artery  stent  thrombosis  is  an  uncommon  but  potentially  catastrophic
complication.  The  risk  of  very  late  stent  thrombosis  (VLST)  raises  important  safety  issues
regarding  the  ﬁrst  generation  of  drug-eluting  stents  (DES).  Although  several  complex  mech-
anisms for  VLST  have  been  suggested  and  various  predictors  have  been  described,  its
pathophysiology  is  not  completely  understood  and  it  is  not  known  whether  longer-term  dual
antiplatelet  therapy  reduces  the  risk.  We  present  a  rare  case  of  simultaneous  very  late  DES
thrombosis  in  the  three  vascular  territories,  following  discontinuation  of  antiplatelet  therapy
seven years  after  stent  placement,  presenting  as  cardiogenic  shock.
© 2012  Sociedade  Portuguesa  de  Cardiologia  Published  by  Elsevier  España,  S.L.  All  rights
reserved.
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Trombose  tripla,  simultânea,  muito  tardia  de  stents  coronários
Resumo  A  trombose  de  stent  coronário  é  uma  complicac¸ão  rara  mas  potencialmente  catas-
tróﬁca. O  risco  de  trombose  muito  tardia  de  stent  (TMTS)  tem  levantado  questões  importantes
sobre a  seguranc¸a  do  uso  de  stents  revestidos  com  fármacos  (SRF)  de  primeira  gerac¸ão.  Embora
sejam vários  e  complexos  os  mecanismos  da  TMTS  e  vários  os  preditores  que  têm  sido  descritos,
a sua  ﬁsiopatologia  ainda  não  está  totalmente  esclarecida  e  desconhece-se  se  o  prolongar  da
terapêutica  antiagregante  dupla  reduz  esse  risco.  Descrevemos  um  caso  raro  de  trombose  muito
loaded from http://www.elsevier.pt, day 04/11/2014. This copy is for personal use. Any transmission of this document by any media or format is strictly prohibited.tardia de  SRF  ocorrendo  em  simultâneo  nos  três  territórios  vasculares,  após  interrupc¸ão  da  ter-
apêutica antiagregante,  sete  anos  após  implantac¸ão  dos  stents,  apresentando-se  como  choque
cardiogénico.
© 2012  Sociedade  Portuguesa  de  Cardiologia.  Publicado  por  Elsevier  España,  S.L.  Todos  os
direitos reservados.∗ Corresponding author.
E-mail address: zemiguelvieira@gmail.com (M.S. Vieira).
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e  present  the  case  of  a  49-year-old  man  with  a  past  his-
ory  of  non-Q  wave  myocardial  infarction  (MI)  seven  years
ia  Published  by  Elsevier  España,  S.L.  All  rights  reserved.
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Figure  1  Top:  Left  anterior  oblique  view  of  the  mid-right  coronary  artery  critical  stenosis  (Panel  A),  right  anterior  oblique  cranial
v is  (P
o hic  r
s
b
t
r
H
h
(
e
w
l
i
u
i
S
s
w
s
a
a
w
I
t
t
o
o
d
p
g
a
n
c
n
r
a
e
a
b
d
i
e
Document downloaded from http://www.elsevier.pt, day 04/11/2014. This copy is for personal use. Any transmission of this document by any media or format is strictly prohibited.iew of  the  mid-left  anterior  descending  artery  critical  stenos
btuse marginal  critical  stenosis  (Panel  C).  Bottom:  Angiograp
irolimus-eluting  stents  (arrowheads)  (D--F).
efore,  with  three-vessel  disease  (right  dominant  circula-
ion),  who  underwent  complete  functional  percutaneous
evascularization  with  sirolimus-eluting  stents  (Figure  1).
e  had  an  unremarkable  follow-up  under  medical  therapy,
aving  completed  12  months  of  dual  antiplatelet  therapy
DAPT),  with  no  residual  angina,  normal  left  ventricular
jection  fraction  and  good  functional  capacity,  although
ith  suboptimal  control  of  cardiovascular  risk  factors  (dys-
ipidemia  and  overweight).  No  in-stent  restenosis  was  noted
n  elective  angiography  at  six  months  and  he  had  no  resid-
al  ischemia  on  exercise  radionuclide  myocardial  perfusion
maging  performed  six  years  later.
Seven  years  later,  the  patient  was  admitted  with  acute
T-segment  elevation  myocardial  infarction,  eight  days  after
topping  aspirin.  Also  notable  was  a  gout  attack  in  the
eek  of  the  cardiac  event.  He  presented  with  typical
evere  retrosternal  chest  pain  and  ST-segment  elevation  in
nteroseptal  and  inferior  leads  (Figure  2).  He  was  immedi-
tely  transferred  to  the  cardiac  catheterization  laboratory,
ith  a  door-to-balloon  time  of  40  minutes  and  Killip  class
 on  admission.  Simultaneous  stent  thrombosis  (ST)  in  the
hree  coronary  arteries  was  noted  on  ﬁrst  contrast  injec-
ion  (Figure  3).  Thrombus  aspiration  and  balloon  angioplasty
D
C
tanel  B)  and  right  anterior  oblique  caudal  view  of  the  second
esult  after  PCI  with  balloon  predilatation  and  implantation  of
f the  left  anterior  descending  coronary  artery  achieved
nly  suboptimal  reperfusion.  No-reﬂow  and  bail-out  ensued,
espite  antithrombotic  pharmacotherapy  (aspirin  and  clo-
idogrel  loading  doses,  unfractionated  heparin  and  platelet
lycoprotein  IIb/IIIa  receptor  inhibitors)  and  intracoronary
denosine  administration.  Right  ventricular  pacing  was
eeded  due  to  complete  atrioventricular  block.  Advanced
ardiovascular  life  support  was  then  started  due  to  hemody-
amic  collapse  and  cardiac  asystole.  While  cardiopulmonary
esuscitation  (CPR)  was  being  performed,  right  coronary
rtery  catheterization  was  attempted  through  a  contralat-
ral  femoral  approach  with  thrombus  aspiration,  balloon
ngioplasty  and  stent  implantation.  Despite  intra-aortic
alloon  pump  placement  and  prolonged  CPR,  the  patient
eveloped  several  episodes  of  ventricular  ﬁbrillation  and
ncessant  pulseless  ventricular  tachycardia  and  eventually
xpired.iscussion
oronary  artery  stent  thrombosis  is  a  rare  but  poten-
ial  catastrophic  complication  of  percutaneous  coronary
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Figure  2  Electrocardiogram  on  admission  with  ST-segment  elevation  in  anteroseptal  and  inferior  leads.
Figure  3  Dramatic  simultaneous  very  late  stent  thrombosis  of  the  left  anterior  descending,  second  obtuse  marginal  and  right
coronary arteries  (A  and  B).  Note  the  extensive  positive  remodeling  with  several  aneurysms  in  the  non-stented  proximal  right  coro-
nary artery  reference  segments  (B  and  D).  Suboptimal  reperfusion  and  no-reﬂow  phenomenon  after  thrombus  aspiration,  multiple
balloon dilations,  administration  of  intracoronary  platelet  glycoprotein  IIb/IIIa  receptor  inhibitors  and  adenosine,  right  ventricular
endocavitary pacing  and  intra-aortic  balloon  pump  counterpulsation  (C  and  D).
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ntervention  (PCI),  usually  presenting  as  sudden  death  or
I.1,2 Moreover,  patients  who  survive  the  event  have  a  worse
rognosis  and  are  at  increased  risk  of  another  ST  in  follow-
p.3
The  risk  of  very  late  stent  thrombosis  (VLST)  (occur-
ing  more  than  one  year  after  stent  placement)  raises
ong-term  safety  concerns  regarding  the  ﬁrst  generation  of
ES  (sirolimus-eluting  and  paclitaxel-eluting  stents),  even
hough,  compared  with  bare  metal  stents,  they  were  a  major
reakthrough,  consistently  being  associated  with  reduced
ates  of  angiographic  restenosis  and  ischemia-driven  target
essel  revascularization.4 The  reported  cumulative  rates  of
eﬁnitive  VLST,  according  to  the  Academic  Research  Consor-
ium  deﬁnition,  vary  in  the  literature  depending  on  the
uration  of  follow-up  used,  and  are  slightly  higher  in  obser-
ational  studies.3--8
Delayed  neointimal  coverage  and  a  hypersensitivity
eaction  to  components  of  the  drug-polymer-stent  combina-
ion,  together  with  ongoing  vessel  inﬂammation,  impaired
ealing  and  abnormal  remodeling  leading  to  late  and
ery  late  acquired  stent  malapposition,  have  been  asso-
iated  with  VLST,  but  the  precise  mechanism  is  still
nknown.9--13 Patient-related  factors  (including  compliance
ith  antiplatelet  therapy),  procedural  and  post-procedural
actors  (including  type  and  duration  of  antiplatelet  therapy)
robably  interact  and  predispose  the  patient  to  ST.2,3,10
Endothelial  dysfunction  has  also  been  described  as  an
dverse  consequence  following  coronary  DES  implanta-
ion,  although  its  clinical  signiﬁcance  is  still  unknown.14
n  fact,  although  DES  target  vascular  smooth  muscle
ell  proliferation  and  migration  (neointimal  hyperplasia),
he  key  factors  in  the  development  of  restenosis,  they
mpair  re-endothelialization  and  promote  late  in-stent
eoatherosclerosis,  a  new  concept  whose  precise  mecha-
ism  is  also  unknown,  that  acts  as  another  substrate  for
LST.15,16 This  also  involves  both  proximal  and  distal  non-
tented  reference  segments  and  leads  to  delayed  arterial
ealing,  impairment  of  endothelial  nitric  oxide  synthe-
is  and  imbalance  between  endothelium-derived  relaxing
nd  contracting  factors,  resulting  in  a  thrombogenic  envi-
onment  and  paradoxical  vasoconstriction  of  the  adjacent
egments.10,16 Moreover,  stent-induced  mechanical  changes
n  vessel  geometry  modify  its  response  to  endothelial  injury
nd  have  been  linked  to  the  pathobiology  of  ST.17
To  the  best  of  our  knowledge,  this  is  the  ﬁrst  report  of
 VLST,  81  months  post-PCI,  simultaneously  occurring  in  the
hree  coronary  artery  territories  following  discontinuation
f  antiplatelet  therapy.
The  peri-stent  aneurysms  depicted  on  angiography  sug-
est  extensive  local  positive  vascular  remodeling,  a  known
ate  complication  after  DES  deployment  which  has  also
een  linked  to  very  late  acquired  stent  malapposition
nd  ST;  a  review  of  the  initial  PCI  showed  no  procedure-
elated  mechanical  problems  such  as  residual  dissection
hat  could  have  acted  as  a  substrate  for  the  ﬁnal  extensive
emodeling.18--20 Furthermore,  although  intravascular  ultra-
ound  was  not  performed  due  to  the  dramatic  course  of  the
vent,  the  pronounced  positive  remodeling  suggests  the  pos-
ibility  of  very  late  stent  malapposition,  a  nidus  for  thrombus
ormation.  Unfortunately  there  was  no  histopathological
nalysis  of  thrombus  aspirates  to  search  for  eosinophilic
nﬁltrates,  which  are  common  in  thrombi  from  very  late  DES
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hrombosis  associated  with  hypersensitivity  reactions  to  the
rug--polymer--stent  combination,  and  related  to  the  extent
f  stent  malapposition.10
Several  mechanisms  have  been  implicated  in  this  posi-
ive  vascular  remodeling,  such  as  procedure-related  acute
essel  injury,  hypersensitivity  reactions  to  the  stent  poly-
er  coatings,  toxic  effects  of  antiproliferative  drugs  on  the
essel,  and  even  focal  infections.14--21
We  hypothesize  that  a  complex  interplay  of  several
hrombogenic  factors  probably  acted  together  to  create  this
‘perfect  storm’’  scenario  that  ended  in  a dramatic  triple
tent  thrombosis:  signiﬁcant  underlying  endothelial  dysfunc-
ion  provoking  an  abnormal  response  to  endothelial  shear
tress,  abnormal  rheological  conditions  and  possible  very
ate  acquired  stent  malapposition;  recent  discontinuation  of
ntiplatelet  therapy  (probably  playing  a  pivotal  role);  and  an
nﬂammatory  state  --  a  recent  gout  attack,  which  has  also
een  linked  to  acute  MI.22
Our  report  highlights  the  serious  consequences  of  discon-
inuing  antiplatelet  therapy,  even  several  years  after  DES
eployment  and  for  a  brief  period.  Although  the  optimal
uration  of  DAPT  after  DES  implantation  is  still  unknown,
obust  data  are  only  available  for  up  to  six  months  of
herapy,  and  there  are  other  mechanisms  not  related  to
iscontinuation  of  drug  therapy  implicated  in  VLST,  anec-
otal  cases  like  this  demonstrate  that  there  may  be  no  time
imit  to  the  occurrence  of  this  complication,  and  lifelong
ntiplatelet  therapy  is  mandatory.2,9--12,23,24
Because  there  is  currently  no  established  method  to
dentify  patients  at  high  risk  of  VLST,  a recognized  multi-
actorial  event,  and  there  is  no  deﬁnitive  evidence  on  the
ptimal  duration  of  DAPT,  careful  surveillance  for  poten-
ial  late  complications  in  patients  with  DES  is  crucial.
edication  compliance,  optimization  of  the  PCI  tech-
ique,  quantiﬁcation  of  coronary  artery  disease  complexity
y  the  SYNTAX  score,  shifting  toward  functional  rather
han  visual  guided  angioplasty  and  thus  avoiding  unnec-
ssary  procedures,  using  invasive  (fractional  ﬂow  reserve,
ntravascular  ultrasound,  optical  coherence  tomography,
nd  quantitative  coronary  angiography  after  intracoro-
ary  acetylcholine  infusion  for  evaluation  of  vasomotor
ysfunction)  and  non-invasive  advanced  coronary  imaging
echniques  for  tailored  post-procedure  monitoring,  may
elp  to  reduce  the  incidence  of  this  potentially  devastating
omplication.25--27
The  multifactorial  nature  of  ST  makes  it  difﬁcult
o  predict  and  neither  genotyping  for  reduced-function
ytochrome  P2C19  nor  platelet  function  testing  currently
ave  a  deﬁnite  role.28
Although  new  anticoagulant  and  antiplatelet  therapies
ave  the  potential  to  inﬂuence  future  clinical  decisions
egarding  the  duration  of  DAPT,  the  current  approved
herapies  should  not  be  discontinued  ahead  of  the  rec-
mmendations  in  the  guidelines.  The  era  of  personalized
ntiplatelet  therapy  is  therefore  eagerly  awaited.
Furthermore,  although  there  appears  to  be  a  class  effect
etween  the  different  antiproliferative  drugs,  the  data  on
ew-generation  DES  (with  thinner,  more  biocompatible  and
ven  bioabsorbable  polymers,  different  stent  alloys  with
etter  ﬂexibility,  conformability,  and  deliverability,  and
lternative  drugs)  are  encouraging  and  may  reduce  this
omplication  further.29,30
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Finally,  long-term  follow-up  studies  are  required  to  assess
the  signiﬁcance  and  management  of  late  and  very  late  vas-
cular  pathologic  changes  secondary  to  DES  implantation,
particularly  in-stent  neoatherosclerosis,  abnormal  vasomo-
tion,  acquired  very  late  stent  malapposition  and  coronary
artery  aneurysms,  and  to  improve  our  understanding  of
endothelial  function.
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